Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.06% | 25.50% | -92.96% | -93.37% | -93.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.06% | 25.50% | -92.96% | -93.37% | -93.38% |
| Cost of Revenue | -48.17% | -28.43% | 117.33% | -19.95% | -52.74% |
| Gross Profit | 143.00% | 170.67% | -212.85% | -122.56% | -107.55% |
| SG&A Expenses | -23.02% | -24.20% | 41.86% | 16.77% | -31.93% |
| Depreciation & Amortization | 3.87% | 5.08% | 37.42% | 104.61% | 310.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.27% | -24.37% | -17.00% | -29.30% | -53.41% |
| Operating Income | 34.02% | 33.07% | -199.11% | -1,445.71% | -734.65% |
| Income Before Tax | 458.96% | 398.82% | 454.08% | -63.39% | -1,214.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 447.64% | 388.08% | 391.95% | -59.33% | -2,328.18% |
| Earnings from Discontinued Operations | -86.26% | -86.55% | 1,409.60% | 1,751.61% | 4,588.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 146.51% | 124.38% | -147.27% |
| Net Income | 132.60% | 107.55% | 345.83% | 205.41% | 228.35% |
| EBIT | 34.02% | 33.07% | -199.11% | -1,445.71% | -734.65% |
| EBITDA | 35.10% | 34.15% | -210.58% | -3,669.31% | -520.54% |
| EPS Basic | 133.02% | 107.67% | 346.01% | 205.41% | 228.05% |
| Normalized Basic EPS | 98.31% | 47.86% | -41.94% | -102.82% | -17,800.00% |
| EPS Diluted | 133.02% | 107.67% | 346.01% | 205.41% | 228.05% |
| Normalized Diluted EPS | 98.31% | 47.86% | -41.94% | -102.82% | -17,800.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |